FindTrial
Sign In

yttrium Y 90-edotreotide

RADIATION2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Brain and Central Nervous System TumorsBreast CancerGastrointestinal Carcinoid TumorIslet Cell TumorLung CancerLymphomaMelanoma (Skin)Neoplastic Syndrome

Phase 1

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
CompletedNCT00006368
Novartis PharmaceuticalsBrain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor +5
Start: 1998-01-31End: 2003-11-30Updated: 2013-05-01

Phase 2

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
CompletedNCT00006370
Novartis PharmaceuticalsBreast Cancer, Lung Cancer
Start: 2000-07-31End: 2004-06-30Updated: 2013-05-01